台灣泌尿科醫學會E-School

台灣泌尿科醫學會E-School

Drug Utilization Patterns in Patients with Lower Urinary Tract Dysfunctions (LUTD) in Taiwan_柳瑞明

2023-03-03 • 觀看: 24 • 回應: 0 • 影片
Mirabegron is more tolerable than solifenacin in Sjogren’s syndrome patients with OAB symptoms_曾浩翔

2023-03-03 • 觀看: 15 • 回應: 0 • 影片
Comparative study between behavior therapy and behavior therapy plus mirabegron 50mg in sexually active men with bothersome OAB symptoms – A multicenter, randomized study_林志杰

2023-03-03 • 觀看: 24 • 回應: 0 • 影片
(IS5-1) Optimizing treatment outcomes with immunotherapy in advanced / metastatic UC_溫聖辰

2023-02-13 • 觀看: 18 • 回應: 0 • 影片
(IS4-1) The role of the dual IO treatment in advanced renal cell carcinoma_賴峻毅

2023-02-13 • 觀看: 6 • 回應: 0 • 影片
(IS3-3) Initial Experience of UroLift in Cardinal Tien Hospital (CTH)_廖俊厚

2023-02-13 • 觀看: 4 • 回應: 0 • 影片
(IS3-2) UroLift Experience in Australia_Kiran Hazratwala

2023-02-13 • 觀看: 9 • 回應: 0 • 影片
(IS3-1) Use of fibrin sealant for mesh fixation in laparoscopic hernia repair_闕士傑

2023-02-13 • 觀看: 11 • 回應: 0 • 影片
(LS5-2) Use of fibrin sealant for mesh fixation in laparoscopic hernia repair_Christophe Berney

2023-02-13 • 觀看: 8 • 回應: 0 • 影片
(LS5-1) The role of Hemopatch in radical prostatectomy and pelvic lymph node dissection: what is the current evidence?_Jeremy Teoh

2023-02-13 • 觀看: 5 • 回應: 0 • 影片
(IS2-1) Just another ordinary day? Considerations for ureteral stricture and Allium stent_魏子鈞

2023-02-13 • 觀看: 11 • 回應: 0 • 影片
(SF3-3) 泌尿科醫學會導入CBME評估的試辦計劃_薛又仁

2023-02-13 • 觀看: 6 • 回應: 0 • 影片

Prev
488
489
490
491
492
493
494
495
496
497
Next
/ 1264